H1
PrivateLast Round
Series C
Extension
Jun 9, 2022
Est. Valuation
$773M
Total Funding Raised
$262.1M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
H1 operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series C Extension round in June 2022.
H1 is a healthcare technology company that provides an AI-driven platform for healthcare and life sciences organizations to identify and engage healthcare professionals for clinical research, medical affairs, and commercialization.
Sector
Healthcare & Life Sciences
Verticals
Data Integration, Healthcare Analytics, Workflow Automation, Compliance
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
H1 Comparables
Compare H1 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HiLabs | 86% | |
| Norstella | 83% | |
| Quest Analytics | 83% |
For institutional investors. Book with your work email.
H1 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jun 9, 2022 | ||||
| Debt | Jun 9, 2022 | ||||
| Series C | Nov 16, 2021 | ||||
| Series B | Jul 27, 2021 | ||||
| Series B | Dec 17, 2020 | ||||
Series A | Apr 22, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
H1 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| dRx Capital | Series C |
| Okeanos | Seed |
| Oak HC/FT | Series B |
| HealthX Ventures | Series A |
| Lux Capital | Series C, Series B |
| Lead Edge Capital | Series B |
| Sunwater Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 17, 2026
Successfully acquired and integrated two companies over the past three years.
- Oct 15, 2026
Eli Lilly secured as a key client.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- acquiresSep 9, 2026
h1 acquires Defacto, a healthcare data company specializing in provider network intelligence, in New York on Sep 9th '26.
For institutional investors. Book with your work email.
H1 Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about H1's valuation, stock price, and market status.
Is H1 a public or private company?
H1 is a private company.
What is the current stock price of H1?
H1 is a private company, so its shares have no public market price. Caplight tracks H1's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is H1 worth (valuation)?
H1's valuation is estimated at $773.0M based on funding round data.
Can I buy H1 stock?
H1 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was H1's last funding round?
H1's most recent funding round was Series C Extension on June 9, 2022.
Who are the main investors in H1?
Key investors in H1 include Oak HC/FT, Empactful Capital, Y Combinator, New Dominion Angels, Menlo Ventures.
Will H1 IPO soon?
No public IPO plans have been announced for H1.
How can I track H1 secondary market activity?
Caplight tracks bids, offers, and trades in H1's shares on secondary markets.